PEOPLE - Abingworth Management (UK) makes appointment:
This article was originally published in Clinica
Life sciences investment group Abingworth Management (UK) has appointed Timothy Haines as a partner. He will be responsible for identifying and creating new businesses, and will provide support for existing companies within the Abingworth portfolio. Mr Haines has gone back on his decision to become CEO of UK separations technology company Whatman. Chairman Bob Thian and vice-chairman Tom McNally will continue to take temporary responsibility for the firm's CEO duties.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.